company background image
KPTI

Karyopharm Therapeutics NasdaqGS:KPTI Stock Report

Last Price

US$4.70

Market Cap

US$381.4m

7D

-8.7%

1Y

-21.5%

Updated

10 Dec, 2022

Data

Company Financials +
KPTI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

KPTI Stock Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.

Karyopharm Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karyopharm Therapeutics
Historical stock prices
Current Share PriceUS$4.70
52 Week HighUS$14.73
52 Week LowUS$4.00
Beta-0.12
1 Month Change-13.12%
3 Month Change-12.15%
1 Year Change-21.54%
3 Year Change-71.94%
5 Year Change-49.13%
Change since IPO-70.72%

Recent News & Updates

Recent updates

Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Aug 07
Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade

May 05
Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade

Health Check: How Prudently Does Karyopharm Therapeutics (NASDAQ:KPTI) Use Debt?

Mar 18
Health Check: How Prudently Does Karyopharm Therapeutics (NASDAQ:KPTI) Use Debt?

This Insider Has Just Sold Shares In Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Feb 20
This Insider Has Just Sold Shares In Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade

Feb 12
Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Breakeven In The Near Future

Feb 01
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Expected To Breakeven In The Near Future

Did You Miss Karyopharm Therapeutics' (NASDAQ:KPTI) Impressive 108% Share Price Gain?

Jan 05
Did You Miss Karyopharm Therapeutics' (NASDAQ:KPTI) Impressive 108% Share Price Gain?

Need To Know: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Have Been Selling Shares

Dec 10
Need To Know: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Have Been Selling Shares

Is Karyopharm Therapeutics (NASDAQ:KPTI) Using Debt In A Risky Way?

Nov 19
Is Karyopharm Therapeutics (NASDAQ:KPTI) Using Debt In A Risky Way?

Shareholder Returns

KPTIUS BiotechsUS Market
7D-8.7%0.5%-2.8%
1Y-21.5%-8.6%-19.6%

Return vs Industry: KPTI underperformed the US Biotechs industry which returned -8.6% over the past year.

Return vs Market: KPTI underperformed the US Market which returned -19.6% over the past year.

Price Volatility

Is KPTI's price volatile compared to industry and market?
KPTI volatility
KPTI Average Weekly Movement10.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: KPTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: KPTI's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008442Richard Paulsonhttps://www.karyopharm.com

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics Inc. Fundamentals Summary

How do Karyopharm Therapeutics's earnings and revenue compare to its market cap?
KPTI fundamental statistics
Market CapUS$381.43m
Earnings (TTM)-US$88.06m
Revenue (TTM)US$249.76m

1.5x

P/S Ratio

-4.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KPTI income statement (TTM)
RevenueUS$249.76m
Cost of RevenueUS$153.09m
Gross ProfitUS$96.68m
Other ExpensesUS$184.74m
Earnings-US$88.06m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.09
Gross Margin38.71%
Net Profit Margin-35.26%
Debt/Equity Ratio-215.9%

How did KPTI perform over the long term?

See historical performance and comparison